Neoplasms Clinical Trial
Official title:
Impact of Elimination or Reduction of Dietary Animal Proteins on Cancer Progression and Survival - A Pilot Study
| Verified date | November 2017 |
| Source | Verein Essen und Krebs |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The purposes of this study are
- to test the hypothesis that elimination or reduction of dietary animal proteins leads to
an improved prognosis in tumor patients
- to estimate the effect size and thus to enable sample size calculations for further
studies
- to test the feasibility and tolerance of different diets, especially a vegan diet, in
cancer patients and to proof that a vegan diet does not lead to a deterioration of
health, tumor progression or to malnutrition
- to test the online platform as a study platform
- to test validity of self reported and online generated data
| Status | Completed |
| Enrollment | 326 |
| Est. completion date | December 2016 |
| Est. primary completion date | December 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Diagnosis of cancer - Inclusion in a tumor treatment or follow-up program - Age >18 years Exclusion Criteria: - Psychiatric treatment during the last 3 months - Pregnancy - Breast feeding - BMI < 18,5 kg/m2 - Major difficulties with food intake (swallowing, lack of appetite) limiting food intake - Participation in other studies requiring the attendance to a particular diet |
| Country | Name | City | State |
|---|---|---|---|
| Austria | Verein Essen und Krebs | Vienna |
| Lead Sponsor | Collaborator |
|---|---|
| Rosa Aspalter | University Hospital Regensburg |
Austria,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number / percentage of remissions | Percentages of remissions as defined be complete absence of a tumor - in an ITT (intention to treat) analysis | 6 months | |
| Secondary | Tumor diagnosis and tumor behaviour (complete remission / partial remission / no change / progression) | In the fist questionnaire, tumor history (diagnosis, classification, stage, previous therapy) is entered. At months 0, 3, 6, 12 and 24 tumor stage at present time is asked again. Comparing the staging between time points, tumor behaviour is categorized into four groups: complete remission / partial remission / no change / tumor progression. This will be determined for each participant by two investigator independently. | 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Relapse-free interval | A relapse is defined by a recurrence of a tumor after a tumor free interval. | 0, 3, 6, 12 and 24 months | |
| Secondary | Therapies, therapy tolerability and side-effects (vomiting, nausea, hair loss, weakness, diarrhea, polyneuropathy,...) | The study questionnaire contains questions referring frequently occuring symptoms in cancer patients and wether they are related to a certain therapy or to other factors. The option "others" is included in case the present symptoms are not covered by the listed symptoms. | 0, 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Comorbidities | The study questionnaire contains questions referring frequently occuring diseases other than cancer and wether they are present now or were present in the past. The option "others" is included in case the present disease is not covered by the listed diseases. | 0, 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Medication | The study questionnaire contains questions referring medications and supplements and the dosage. | 0, 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Quality of life | The study questionnaire contains questions referring quality of live covering the Karnofsky Index, but additional dimensions, too (psychosocial wellbeing). | 0, 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Acceptance and feasibility of the selected diet | The study questionnaire contains questions referring ease and difficulties with the selected diet. | 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Dietary pattern | The study questionnaire contains questions referring previous dietary patterns and the dietary pattern which will be followed for the time of study participation (6 months) as well as the reason for choosing the respective diet. There is a categorical question asking for dietary patterns as well a comprehensive food frequency questionnaire especially adopted for discrimination of plant an animal derived foods. In addition to the main study questionnaires, participants are asked to report any unplanned change in their diet during study participation. |
0, 3, 6, 12 and 24 months | |
| Secondary | Frequency, extent and duration of nutritional changes | The results referring to nutrition and dietary patterns are evaluated in terms of change and duration of change in dietary patterns (in months). | 3 and 6 months (optional: 12 and 24 months) | |
| Secondary | Weight and nutritional status | Weight is entered in kg and size in cm. BMI is calculated. Nutritional status is derived from weight changes, laboratory test results (albumin) and questions referring to eating problems contained in the study questionnaire. | 0, 3, 6, 12 and 24 months | |
| Secondary | Experience with / performance of study platform | One question of the questionnaire asks for experience and usability of the comprehensive questionnaire in terms of content, understanding, effort und technical experience. | 0, 3 and 6 months | |
| Secondary | Validity checks for self reported data | Several questions are repeated in the questionnaire in a slightly different way to check for consistency. Dietary patterns are checked via food frequency questionnaires and control questions in the laboratory test section. | 0, 3 and 6 months | |
| Secondary | Survival rates for end stages | Survival rates are calculated from the participants still alive and dead. In case of a pending questionnaire a contact person is asked or a cancer registry checked (depending on the citizenship of the participant). | 6 months, 12 and 24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |